Valneva Seeks FDA Approval for Expanded Vaccine Use

Valneva (VALN) has released an update.

Don't Miss our Black Friday Offers:

Valneva has submitted an application to the U.S. FDA to extend the use of its chikungunya vaccine, IXCHIQ®, to adolescents and highlight its long-term antibody persistence. The vaccine, already approved for adults, showed a 99.1% immune response in adolescents with sustained protection over two years. Valneva aims to increase accessibility and expand market opportunities with potential approvals in new regions.

For further insights into VALN stock, check out TipRanks’ Stock Analysis page.

Trending Articles

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.